Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
November 13 2024 - 6:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 12, 2024
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Trading in Novo Nordisk shares by board members, executives and associated
persons
Bagsværd, Denmark, 12 November 2024 — This company
announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and
their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf
to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
David Moore |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive Vice President, head of Corporate Development |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
Page 2 of 3
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0062498333 |
|
|
| b) |
Nature of the transaction |
Other transaction (acquisition of shares in accordance with the recruitment package) |
| c) |
Price(s) and volume(s) |
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| DKK 0.00 |
18,634 shares |
| d) |
Aggregated information
·
Aggregated volume
·
Price |
18,634 shares
DKK 0.00 |
| e) |
Date of the transaction |
2024-11-11 |
| f) |
Place of the transaction |
Outside a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
David Moore |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive Vice President, head of Corporate Development |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| Identification code |
Novo Nordisk B DK0062498333 |
Page 3 of 3
| b) |
Nature of the transaction |
Sale of Shares |
| c) |
Price(s) and volume(s) |
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| DKK 759.96 |
9,919 shares |
| d) |
Aggregated information
·
Aggregated volume
·
Price |
9,919 shares
DKK 7,538,047.37 |
| e) |
Date of the transaction |
2024-11-11 |
| f) |
Place of the transaction |
Nasdaq Copenhagen |
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access
to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets
its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New
York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and
YouTube.
Contacts for further information
| Media: |
|
|
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com |
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com |
| |
|
| Investors: |
|
|
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com |
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
| |
|
|
Sina Meyer
+45 3079 6656
azey@novonordisk.com |
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com |
| |
|
Frederik Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com
|
|
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company
announcement No 87 / 2024 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: November 12, 2024 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Dec 2024 to Jan 2025
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jan 2024 to Jan 2025
